首页> 外文OA文献 >Phase I Dose-Escalation Study of Anti–CTLA-4 Antibody Ipilimumab and Lenalidomide in Patients with Advanced Cancers

【2h】

Phase I Dose-Escalation Study of Anti–CTLA-4 Antibody Ipilimumab and Lenalidomide in Patients with Advanced Cancers

机译：抗CTLA-4抗体IPILIMILAB和Lenalidomide患者晚期癌症的I相剂量 - 升级研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Divya Sakamuri; Isabella C. Glitza; Sonia L. Betancourt Cuellar; Vivek Subbiah; Siqing Fu; Apostolia M. Tsimberidou; Jennifer J. Wheler; David S. Hong; Aung Naing; Gerald S. Falchook; Michelle A. Fanale; Maria E. Cabanillas; Filip Janku;
展开▼
作者单位

展开▼
年度 2017
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Phase I Dose-Escalation Study of Anti–CTLA-4 Antibody Ipilimumab and Lenalidomide in Patients with Advanced Cancers [J] . Divya Sakamuri, Isabella C. Glitza, Sonia L. Betancourt Cuellar, Molecular cancer therapeutics . 2018,第3期

机译：抗CTLA-4抗体IPILIMIMAB和Lenalidomide患者晚期癌症的I期剂量 - 升级研究
2. A phase I, dose-escalation study of PF-06650808, an anti-Notch3 antibody-drug conjugate, in patients with breast cancer and other advanced solid tumors [J] . Rosen Lee S., Wesolowski Robert, Baffa Raffaele, Ecological restoration . 2020,第1期

机译：乳腺癌和其他先进实体肿瘤的患者，PF-06650808，抗Notch3抗体 - 药物缀合物的I阶段升级研究，患者
3. A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer [J] . Kerry Lynn Reynolds, Philippe L. Bedard, Se-Hoon Lee, BMC Cancer . 2017,第1期

机译：抗HER3单克隆抗体LJM716在晚期食道或头颈部鳞状细胞癌和HER2过表达的乳腺癌或胃癌患者中的I期开放标签剂量递增研究
4. A Bispecific Antibody Targeting CD40 and CTLA-4 Generates Anti-Tumor Effects and Tumor Immunity [C] . Peter Ellmark, Karin Enell Smith, Niina Veitonmaki, PEGS . 2015

机译：靶向CD40和CTLA-4的双特异性抗体产生抗肿瘤作用和肿瘤免疫力
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. Phase 1 dose-escalation study of anti CTLA-4 antibody ipilimumab and lenalidomide in patients with advanced cancers [O] . Divya Sakamuri, Isabella C. Glitza, Sonia L. Betancourt Cuellar, -1

机译：抗CTLA-4抗体ipilimumab和来那度胺在晚期癌症患者中的1期剂量递增研究
7. 138 Phase 1 dose-escalation study of STRO-002, an anti-folate receptor alpha (FRα) antibody drug conjugate (ADC), in patients with advanced platinum-resistant/refractory epithelial ovarian cancer (OC) [O] . R Naumann, F Braiteh, J Diaz, 2020

机译：138阶段1剂量 - 抗叶酸受体α（FRα）抗体药物缀合物（ADC）的抗叶酸受体α（FRα）抗体药物缀合物（ADC），抑制铂抗性/难治性上皮卵巢癌（OC）

Phase I Dose-Escalation Study of Anti–CTLA-4 Antibody Ipilimumab and Lenalidomide in Patients with Advanced Cancers

著录项

引文网络

相似文献

相关主题

期刊订阅